Format

Send to

Choose Destination
Oncologist. 2019 Nov;24(11):1497-1501. doi: 10.1634/theoncologist.2019-0316. Epub 2019 Aug 9.

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Author information

1
Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA daniel.george@duke.edu.
2
Exelixis, Inc., Alameda, California, USA.
3
Alliance Statistics and Data Center, and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
4
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
5
Alliance Protocol Operations Office, Chicago, Illinois, USA.
6
Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
7
Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
8
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
9
University of Kansas - Wichita, Wichita, Kansas, USA.
10
Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Abstract

Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number NCT01835158.

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center